Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

244
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
244
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

512
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
512
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

478
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
478
Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

654
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
654

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors associated with psychological distress among end-of-life care volunteers: a systematic review of quantitative and qualitative evidence.

BMC palliative care·2026
Same author

Measuring the Prodrome Promise and Challenges of the Prodromal Synucleinopathy Rating Scale.

Neurology·2026
Same author

Effect of subcutaneous foslevodopa/foscarbidopa therapy on non-motor symptoms in advanced PD patients.

Journal of neurology·2026
Same author

Subthalamic segmentations in relation to deep brain stimulation volumes in Parkinson's disease.

Acta neurochirurgica·2026
Same author

Clinical implementation of ultra-low-field portable MRI in the neuro-intensive care and stroke unit.

Neuroradiology·2026
Same author

Detection of Hemorrhagic Transformation of Cerebral Infarcts with Ultra-low Field MRI.

Clinical neuroradiology·2026

Related Experiment Video

Updated: Jun 19, 2025

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

14.0K

Tips and tricks in tremor treatment.

Franziska Hopfner1, Carsten Buhmann2, Joseph Classen3

  • 1Department of Neurology, Neurologische Klinik und Poliklinik mit Friedrich Baur Institut, Ludwig-Maximilians University, Campus Großhadern, Marchioninistraße 15, 81377, Munich, Germany. franziska.hopfner@med.uni-muenchen.de.

Journal of Neural Transmission (Vienna, Austria : 1996)
|July 23, 2024
PubMed
Summary

Effective tremor management involves tailored strategies for various causes, including Parkinson's disease and essential tremor. Treatments range from medications like levodopa and propranolol to advanced therapies and non-drug interventions for improved quality of life.

Keywords:
TremorTremor treatment

More Related Videos

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

39.7K
A Simple Non-invasive Method for Temporary Knockdown of Upper Limb Proprioception
07:42

A Simple Non-invasive Method for Temporary Knockdown of Upper Limb Proprioception

Published on: March 3, 2018

9.4K

Related Experiment Videos

Last Updated: Jun 19, 2025

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

14.0K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

39.7K
A Simple Non-invasive Method for Temporary Knockdown of Upper Limb Proprioception
07:42

A Simple Non-invasive Method for Temporary Knockdown of Upper Limb Proprioception

Published on: March 3, 2018

9.4K

Area of Science:

  • Neurology
  • Pharmacology
  • Biomedical Engineering

Background:

  • Tremor significantly impacts patient quality of life, necessitating effective treatment algorithms.
  • Diverse etiologies of tremor, including neurological diseases, other conditions, and medication side effects, present complex management challenges.

Purpose of the Study:

  • To review current treatment strategies for various tremor types.
  • To highlight the importance of personalized management approaches considering patient needs and tolerability.

Main Methods:

  • Review of pharmacological treatments: Levodopa, dopamine agonists, propranolol, primidone, anticholinergics, clozapine, 1-Octanol, and anticonvulsants.
  • Exploration of advanced therapies: Deep brain stimulation and focused ultrasound for resistant cases.
  • Inclusion of non-drug interventions: Sensor-based detection, wristbands, and physical therapy.

Main Results:

  • Levodopa is key for Parkinson's tremor, with variable response.
  • Propranolol is effective for essential tremor (ET/ET+), sometimes combined with primidone.
  • Reserve medications and advanced therapies address specific or resistant tremor types.
  • Medication review is critical, especially for drug-induced tremors.

Conclusions:

  • Optimal tremor management requires integrating pharmacological, non-invasive, and technological approaches.
  • Tailored strategies considering patient-specific factors are essential for symptom control and improved quality of life.
  • Emerging sensor-based and non-drug interventions offer promising future enhancements in tremor care.